Treatment of rheumatoid arthritis (RA) with monoclonal anti-tumor necrosis factor α antibody (anti-TNFα mAb) results in an accumulation of TH1 CD4+ T cells in the peripheral blood.

被引：0
|
作者：
Maurice, MM
van der Graaft, WL
Leow, A
Breedveld, FC
van Lier, RAW
Verweij, CL
机构：
[1] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[2] Red Cross Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, Amsterdam, Netherlands
[3] Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [31] T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment .2. Clinical activity is related to pharmacodynamic effects
    Choy, EHS
    Connolly, DJA
    Regan, T
    Manna, VK
    Rapson, N
    Kingsley, GH
    Panayi, GS
    Johnston, JM
    IMMUNOLOGY, 1996, 89 : OG378 - OG378
  • [32] Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo controlled multicenter trial.
    Kavanaugh, AF
    Cush, JJ
    StClair, EW
    McCune, WJ
    Braakman, TAJ
    Nichols, LA
    Linsky, PE
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 575 - 575
  • [33] IMBALANCE OF TH1 AND TH2 SUBSETS IN MICE PARTIALLY DEPLETED OF CD4 T-CELLS BY ANTI-CD4 MONOCLONAL-ANTIBODY
    FIELD, EH
    ROUSE, TM
    JAMALI, I
    COWDERY, JS
    FASEB JOURNAL, 1992, 6 (04): : A1418 - A1418
  • [34] Evaluation of T Helper Cell 1(Th1) - and T Helper Cell 17(Th17) - Associated Chemokines As Prognostic Biomarkers for Tumor Necrosis Factor (TNF) Inhibitor Therapy in Rheumatoid Arthritis (RA)
    Han, Bobby Kwanghoon
    Bottaro, Andrea
    Kuzin, Igor
    Olsen, Nancy J.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment .1. Suppression of disease activity and acute phase response
    Panayi, GS
    Choy, EHS
    Connolly, DJA
    Regan, T
    Manna, VK
    Rapson, N
    Kingsley, GH
    Johnston, JM
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1300 - 1300
  • [36] Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments
    Jean-Luc Davignon
    Jean-Frédéric Boyer
    Bénédicte Jamard
    Delphine Nigon
    Arnaud Constantin
    Alain Cantagrel
    Arthritis Research & Therapy, 12
  • [37] Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4
    Schulze-Koops, H
    Davis, LS
    Haverty, TP
    Wacholtz, MC
    Lipsky, PE
    JOURNAL OF RHEUMATOLOGY, 1998, 25 (11) : 2065 - 2076
  • [38] Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial (vol 48, pg 35, 2003)
    Weinblatt, ME
    Keystone, EC
    Furst, DE
    Moreland, LW
    Weisman, MH
    Birbara, CA
    Teoh, LA
    Fischkoff, SA
    Chartash, EK
    ARTHRITIS AND RHEUMATISM, 2003, 48 (03): : 855 - 855
  • [39] Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients
    Choy, EHS
    Connolly, DJA
    Rapson, N
    Jeal, S
    Brown, JCC
    Kingsley, GH
    Panayi, GS
    Johnston, JM
    RHEUMATOLOGY, 2000, 39 (10) : 1139 - 1146
  • [40] TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS WITH A CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY - LONG-TERM FOLLOW-UP OF CD4+ T-CELL COUNTS
    MORELAND, LW
    PRATT, PW
    BUCY, RP
    JACKSON, BS
    FELDMAN, JW
    KOOPMAN, WJ
    ARTHRITIS AND RHEUMATISM, 1994, 37 (06): : 834 - 838
12345